TrialThe oncologist2021

Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.

Huabin Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.